No Picture
Los Angeles Biotech News

Preliminary Data from Long-Term Safety Study Support Chronic Use of ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis

WESTLAKE VILLAGE, Calif., July 31, 2020 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological di… […]

No Picture
Los Angeles Biotech News

Emmaus Life Sciences Provides Additional Operational and OTC Markets Updates

TORRANCE, Calif, July 31, 2020 (GLOBE NEWSWIRE) — Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, provided today additional operational updates for the year ended December 31, 2019 as well as operational updates … […]

No Picture
Los Angeles Biotech News

Tiger Woods, USTA, Disney and Leading Philanthropists Pledge $50 Million Toward Massive Youth Complex Focused on Education Equity and Sports Access in Los Angeles

CARSON, Calif.–(BUSINESS WIRE)–Tiger Woods’ TGR Foundation, the United States Tennis Association (USTA), The Walt Disney Company, philanthropist Doug Kimmelman and the Karsh Family Foundation have committed $50 million toward the nation’s largest aca… […]

No Picture
Los Angeles Biotech News

Tetraphase deal done, La Jolla Pharmaceutical taps Larry Edwards as CEO; Longtime Eli Lilly exec Michael Overdorf heads to Annexon as CBO

Larry Edwards
→ As La Jolla Pharmaceutical closed on their acquisition of Tetraphase on Wednesday, the San Diego biotech also announced that they’re taking the president and CEO right along with them as Larry Edwards steps in. Edwards, who had a 15-yea… […]

No Picture
Los Angeles Biotech News

Endologix Announces First Commercial Implant of ALTO Abdominal Stent Graft System & Official Start of U.S. Commercial Release

IRVINE, Calif.–(BUSINESS WIRE)–Endologix announces first commercial implant of ALTO Abdominal Stent Graft System & official start of U.S. commercial release […]

No Picture
Los Angeles Biotech News

AbbVie preps a challenge to a rival migraine drug from Biohaven, spelling out an upbeat set of PhIII data

Phase III advance trial data for AbbVie’s migraine prevention drug atogepant look good — but are the results good enough to rival Biohaven’s two-in-one treatment and prevention drug, rimegepant, sold as Nurtec?
AbbVie picked up atogepant from Allergan … […]

No Picture
Los Angeles Biotech News

Emmaus Life Sciences Receives Scientific Advice From the EMA Regarding Xyndari™

TORRANCE Calif., July 29, 2020 (GLOBE NEWSWIRE) — Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that the European Medicines Agency (EMA) issued scientific advice to Emmaus regarding the clinical… […]

No Picture
Los Angeles Biotech News

Xencor to Host Second Quarter 2020 Financial Results Webcast and Conference Call on August 4, 2020

MONROVIA, Calif.–(BUSINESS WIRE)–Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will release second quart… […]

No Picture
Los Angeles Biotech News

Amgen dumps early-stage CD38xCD3 bispecific, returning rights to Xencor picked up in 2015 alliance

Five years after Amgen $AMGN agreed to wager up to $1.8 billion on an alliance with Xencor that spotlighted their preclinical bispecific T cell engager program directed at CD38 and CD3 for multiple myeloma, the big biotech is walking away from the prog… […]